Trends in Opioid Use Disorder Diagnoses and Medication Treatment Among Veterans With Posttraumatic Stress Disorder

• Published in: Journal of dual diagnosis 2017-07, Vol.13 (3), p.201-212
• Main Authors: Shiner, Brian, Leonard Westgate, Christine, Bernardy, Nancy C., Schnurr, Paula P., Watts, Bradley V.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Analgesics, Opioid - therapeutic use; Buprenorphine - therapeutic use; Comorbidity; Drug abuse; Drug addiction; electronic health records; Female; health services research; Humans; Male; Methadone - therapeutic use; Middle Aged; Naltrexone - therapeutic use; Narcotics; opioid-related disorders; Opioid-Related Disorders - drug therapy; Opioid-Related Disorders - epidemiology; pharmacoepidemiology; Post traumatic stress disorder; posttraumatic; psychotropic drugs; Stress disorder; Stress Disorders, Post-Traumatic - epidemiology; Stress Disorders, Post-Traumatic - therapy; Substance abuse treatment; Substance use disorder; Time Factors; United States; United States Department of Veterans Affairs; Veterans; Young Adult
• ISSN: 1550-4263; 1550-4271; 1550-4271
• DOI: 10.1080/15504263.2017.1325033

Objective: Despite long-standing interest in posttraumatic stress disorder (PTSD) and opioid use disorder comorbidity, there is a paucity of data on the prevalence of opioid use disorder in patients with PTSD. Therefore, there is limited understanding of the use of medications for opioid use disorder in this population. We determined the prevalence of diagnosed opioid use disorder and use of medications for opioid use disorder in a large cohort of patients with PTSD. Methods: We obtained administrative and pharmacy data for veterans who initiated PTSD treatment in the Department of Veterans Affairs (VA) between 2004 and 2013 (N = 731,520). We identified those with a comorbid opioid use disorder diagnosis (2.7%; n = 19,998) and determined whether they received a medication for opioid use disorder in the year following their initial clinical PTSD diagnosis (29.6%; n = 5,913). Using logistic regression, we determined the predictors of receipt of opioid use disorder medications. Results: Comorbid opioid use disorder diagnoses increased from 2.5% in 2004 to 3.4% in 2013. Patients with comorbid opioid use disorder used more health services and had more comorbidities than other patients with PTSD. Among patients with PTSD and comorbid opioid use disorder, use of medications for opioid use disorder increased from 22.6% to 35.1% during the same time period. Growth in the use of buprenorphine (2.0% to 22.7%) was accompanied by relative decline in use of methadone (19.3% to 12.7%). Patients who received buprenorphine were younger and more likely to be rural, White, and married. Patients who received methadone were older, urban, unmarried, from racial and ethnic minorities, and more likely to see substance abuse specialists. While use of naltrexone increased (2.8% to 8.6%), most (87%) patients who received naltrexone also had an alcohol use disorder. Controlling for patient factors, there was a substantial increase in the use of buprenorphine, a substantial decrease in the use of methadone, and no change in use of naltrexone across years. Conclusions: Opioid use disorder is an uncommon but increasing comorbidity among patients with PTSD. Patients entering VA treatment for PTSD have their opioid use disorder treated with opioid agonist treatments in large and increasing numbers. There is a need for research both on the epidemiology of opioid use disorder among patients with PTSD and on screening for opioid use disorder.